Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 血漿交換術 | から $2,200 | から $1,200 | から $2,000 |
| 血漿交換 | - | から $3,900 | - |
| 治療的アフェレーシス | - | から $1,350 | - |
| カスケードプラズマろ過 | - | から $1,850 | - |
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Israel offers advanced multiple myeloma treatments including in-house developed CAR T-cell therapy, bispecific antibodies, and complex stem cell transplants. Facilities like Sheba Medical Center and Hadassah provide personalized precision medicine. These programs utilize genetic profiling to tailor targeted drug protocols for refractory cases.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba are unique because they perform both pediatric and adult bone marrow transplants at massive scale. Dr. Fredi Aviv has practiced at Sourasky for over 30 years, while Sheba serves nearly 2 million patients annually. This high volume allows doctors to manage complex side effects from aggressive daratumumab combinations more effectively than smaller regional centers.
Patient Consensus: Patients note that access to tandem transplants is often faster in Israel than in the US. Many suggest prioritizing bispecific antibodies over CAR-T if you have limited mobility, as the administration process is simpler.
Israeli clinics achieve CAR-T therapy success rates between 70% and 90% for various blood cancers. Medical centers like Sheba and Hadassah report a 90% overall response rate for multiple myeloma. These results frequently exceed global averages due to advanced in-house cell manufacturing and early clinical adoption.
Bookimed Expert Insight: Israeli centers like Sheba Medical Center offer a distinct advantage through point-of-care manufacturing. While commercial labs usually take 3 to 4 weeks, Sheba's in-house facility delivers cells in roughly 10 days. This speed prevents disease progression during the waiting period. Advanced specialists like Dr. Abraham Avigdor and Dr. Avichai Shimoni lead these high-volume programs with over 30 years of experience.
Patient Consensus: Patients note that while deep remissions are common, it is vital to discuss long-term durability with the medical team. People often emphasize that the faster cell processing in Israel provides significant peace of mind during the critical treatment window.
Israel boasts internationally recognized myeloma specialists at JCI-accredited institutions like Sheba Medical Center and Sourasky Medical Center. These experts include Prof. Avichai Shimoni and Dr. Hila Magen, both leading figures in immunotherapy and stem cell transplantation for plasma cell disorders.
Bookimed Expert Insight: Israeli oncology centers demonstrate high-volume expertise, with Sourasky Medical Center serving 1.8 million patients and maintaining a 90% success rate. Experts like Dr. Hila Magen and Dr. Abraham Avigdor have over 30 years of experience. This deep specialization is why many specialists are listed among Forbes' Top Doctors.
Patient Consensus: Patients note the value of specialists who participate in international clinical trials. Many seek out physicians like Prof. Michael Shapira for personalized bone marrow transplant protocols.
Israel offers numerous clinical trials for relapsed and high-risk myeloma patients. Major centers utilize advanced CAR T-cell therapies and bispecific antibodies. These trials provide access to innovative treatments for those not responding to standard care. Facilities like Sheba Medical Center are global leaders in immunotherapy research.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba have massive patient volumes, exceeding 1,800,000 yearly. This high throughput accelerates trial enrollment and data collection. Patients benefit from a 90% success rate in general oncology at specialized Tel Aviv facilities. Clinicians often combine research with practical care, as seen by their rankings in the global top 10 for consecutive years.
Patient Consensus: Patients value the direct access to Nobel-prize-winning expertise and latest CAR-T protocols. Many emphasize that coordinate Care in Israel feels exceptionally personalized despite the massive size of the hospitals.
Myeloma treatment in Israel typically requires a stay of 1 to 8 weeks depending on the protocol. Diagnostics usually conclude within 5 days. Complex therapies like CAR-T cell infusion require intensive monitoring for approximately 8 weeks. Standard chemo-immunotherapy cycles often allow patients to return home between sessions.
Bookimed Expert Insight: Israeli oncology centers like Sourasky or Sheba often fast-track international cases to avoid local wait times. While residents may wait significantly longer for elective care, international patients typically begin specialized diagnostics immediately upon arrival. This efficiency is critical for myeloma patients who require rapid intervention after a diagnosis is confirmed.
Patient Consensus: Patients note that staying in a nearby hotel rather than the hospital for follow-up days makes the recovery process much more comfortable and less stressful.